


Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A33081-R 072771.0106	Serial No. 09/633,034
	Applicant Tsang <i>et al.</i>	
	Filing Date August 4, 2000	Group 1642
	Examiner Helms, L.R.	

U.S. PATENT DOCUMENTS							
*Exam. Initial.	No.	Document No.	Date	Name	Class	Subclass	Filing Date if Approximate.
SJH	11	6,346,249	February 12, 2002	Barbas III et al.			4/4/2000.
SJH	12	6,342,587	January 29, 2002	Barbas III et al.			10/22/1999
SJH	28	5,958,412	Sept. 28, 1999	Welt et al.			6/4/1997
SJH	33	5,712,369	January 27, 1998	Welt et al. Old et al.			2/2/1996.
↓	39	5,643,550	July 1, 1997	Welt et al.			9/27/1994
↓	47	5,160,723	November 3, 1991	Welt et al.			3/18/ 1991.

FOREIGN PATENT DOCUMENTS							
Exam Initial	No.	Document No.	Date	Country	Class	Subclass	Translation Yes No

NY02:524633.3	Examiner 	Date Considered 11/7/05
---------------	---	----------------------------

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A33081-R 072771.0106	Serial No. 09/633,034
	Applicant Tsang <i>et al.</i>	
	Filing Date August 4, 2000	Group 1642
	Examiner Helms, L.R.	


Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
SM	1	Chong, G., F. T. Lee, et al. (2005). "Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma." Clin Cancer Res 11(13): 4818-26.
	2	Koppe, M. J., R. P. Bleichrodt, et al. (2005). "Radioimmunotherapy and colorectal cancer." Br J Surg 92(3): 264-276.
	3	Mallegol, J., G. van Niel, et al. (2005). "Phenotypic and functional characterization of intestinal epithelial exosomes." Blood Cells Mol Dis 35(1): 11-16.
	4	Scott, A. M., F. T. Lee, et al. (2005). "A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake." Clin Cancer Res 11(13): 4810-4817.
	5	Deckert, P. M., W. G. Bommann, et al. (2004). "Specific tumour localisation of a huA33 antibody--carboxypeptidase A conjugate and activation of methotrexate-phenylalanine." Int J Oncol 24(5): 1289-95.
	6	Joosten, C. E., L. S. Cohen, et al. (2004). "Glycosylation profiles of the human colorectal cancer A33 antigen naturally expressed in the human colorectal cancer cell line SW1222 and expressed as recombinant protein in different insect cell lines." Biotechnol Prog 20(4): 1273-9.
	7	Deckert, P. M., C. Renner, et al. (2003). "A33scFv-cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy." Br J Cancer 88(6): 937-9.
	8	Mao, Z., S. Song, et al. (2003). "Transcriptional regulation of A33 antigen expression by gut-enriched Kruppel like factor." Oncogene 22(28): 4434-43.
	9	Welt et al., 2003, Phase I Study of Anticolon Cancer Humanized Antibody A331. Clinical Cancer Res. 9(4):1338-1346.

NY02:524633.3		
Examiner	<i>SM</i>	Date Considered 11/7/05

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A33081-R 072771.0106	Serial No. 09/633,034
	Applicant Tsang <i>et al.</i>	
	Filing Date August 4, 2000	Group 1642
	Examiner Helms, L.R.	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
551	10	Welt, S., G. Ritter, et al. (2003). "Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer." Clin Cancer Res 9(4): 1347-53.
	13	Johnstone, C. N., S. J. White, et al. (2002). "Analysis of the regulation of the A33 antigen gene reveals intestine-specific mechanisms of gene expression." J Biol Chem 277(37): 34531-9.
	14	Orlova, A., J. Hoglund, et al. (2002). "Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33. Implications for in vivo dosimetry." Cancer Biother Radiopharm 17(4): 385-96.
	15	van Niel, G. and M. Heyman (2002). "The epithelial cell cytoskeleton and intracellular trafficking. II. Intestinal epithelial cell exosomes: perspectives on their structure and function." Am J Physiol Gastrointest Liver Physiol 283(2): G251-5.
	16	Barendswaard, E. C., J. L. Humm, et al. (2001). "Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft." J Nucl Med 42(8): 1251-6.
	17	Lee, F. T., A. Rigopoulos, et al. (2001). "Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts." Cancer Res 61(11): 4474-82.
	18	Ritter, G., L. S. Cohen, et al. (2001). "Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33." Cancer Res 61(18): 6851-9.
	19	van Niel, G., G. Raposo, et al. (2001). "Intestinal epithelial cells secrete exosome-like vesicles." Gastroenterology 121(2): 337-49.
✓	20	Abud, H. E., C. N. Johnstone, et al. (2000). "The murine A33 antigen is expressed at two distinct sites during development, the ICM of the blastocyst and the intestinal epithelium." Mech Dev 98(1-2): 111-4.

NY02:524633.3	
Examiner 	Date Considered 11/7/05

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A33081-R 072771.0106	Serial No. 09/633,034
	Applicant Tsang <i>et al.</i>	
	Filing Date August 4, 2000	Group 1642
	Examiner Helms, L.R.	


Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
SM	21	Deckert, P. M., A. Jungbluth, et al. (2000). "Pharmacokinetics and microdistribution of polyethylene glycol-modified humanized A33 antibody targeting colon cancer xenografts." <i>Int J Cancer</i> 87(3): 382-90.
	22	Johnstone, C. N., N. C. Tebbutt, et al. (2000). "Characterization of mouse A33 antigen, a definitive marker for basolateral surfaces of intestinal epithelial cells." <i>Am J Physiol Gastrointest Liver Physiol</i> 279(3): G500-10.
	23	Rader, C., G. Ritter, et al. (2000). "The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies." <i>J Biol Chem</i> 275(18): 13668-76.
	24	Ruan, S., J. A. O'Donoghue, et al. (2000). "Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam." <i>J Nucl Med</i> 41(11): 1905-12.
	25	Sakamoto, J., H. Kojima, et al. (2000). "Organ-specific expression of the intestinal epithelium-related antigen A33, a cell surface target for antibody-based imaging and treatment in gastrointestinal cancer." <i>Cancer Chemother Pharmacol</i> 46 Suppl: S27-32.
	26	Barendswaard, E. C., J. A. O'Donoghue, et al. (1999). "131I radioimmunotherapy and fractionated external beam radiotherapy: comparative effectiveness in a human tumor xenograft." <i>J Nucl Med</i> 40(10): 1764-8.
	27	Miyazono, Y., Y. Kamogawa, et al. (1999). "Effect of B7.1-transfected human colon cancer cells on the induction of autologous tumour-specific cytotoxic T cells." <i>J Gastroenterol Hepatol</i> 14(10): 997-1003.
	29	Barendswaard, E. C., A. M. Scott, et al. (1998). "Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice." <i>Int J Oncol</i> 12(1): 45-53.
✓	30	Burgess, A. W. (1998). "Growth control mechanisms in normal and transformed intestinal cells." <i>Philos Trans R Soc Lond B Biol Sci</i> 353(1370): 903-9.

NY02:524633.3	Examiner	<i>Stuft</i>	Date Considered	11/7/05
---------------	----------	--------------	-----------------	---------

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A33081-R 072771.0106	Serial No. 09/633,034
	Applicant Tsang <i>et al.</i>	
	Filing Date August 4, 2000	Group 1642
	Examiner Helms, L.R.	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
5371	31	Moritz, R. L., G. Ritter, et al. (1998). "Micro-sequencing strategies for the human A33 antigen, a novel surface glycoprotein of human gastrointestinal epithelium." J Chromatogr A 798(1-2): 91-101.
	32	Tio, T. L. (1998). "Diagnosis and staging of esophageal carcinoma by endoscopic ultrasonography." Endoscopy 30 Suppl 1: A33-40.
	34	Catimel, B., M. Nerrie, et al. (1997). "Kinetic analysis of the interaction between the monoclonal antibody A33 and its colonic epithelial antigen by the use of an optical biosensor. A comparison of immobilisation strategies." J Chromatogr A 776(1): 15-30.
	35	Heath, J. K., S. J. White, et al. (1997). "The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily." Proc Natl Acad Sci U S A 94(2): 469-74.
	36	Ji, H., R. L. Moritz, et al. (1997). "Electrophoretic analysis of the novel antigen for the gastrointestinal-specific monoclonal antibody, A33." Electrophoresis 18(3-4): 614-21.
	37	Ritter, G., L. S. Cohen, et al. (1997). "Characterization of posttranslational modifications of human A33 antigen, a novel palmitoylated surface glycoprotein of human gastrointestinal epithelium." Biochem Biophys Res Commun 236(3): 682-6.
	38	Tschmelitsch, J., E. Barendswaard, et al. (1997). "Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil)." Cancer Res 57(11): 2181-6.
	40	No Author listed. (1996). "MoAb A33 shows promise in targeting colon cancer for radioimmunotherapy." Oncology (Huntingt) 10(4): 553.
	41	Antoniw, P., A. P. Farnsworth, et al. (1996). "Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM)." Br J Cancer 74(4): 513-24.

NY02:524633.3		
Examiner		Date Considered 11/7/05

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A33081-R 072771.0106	Serial No. 09/633,034
	Applicant Tsang <i>et al.</i>	
	Filing Date August 4, 2000	Group 1642
	Examiner Helms, L.R.	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
557	42	Daghighian, F., E. Barendswaard, et al. (1996). "Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody." J Nucl Med 37(6): 1052-7.
	43	Welt, S., A. M. Scott, et al. (1996). "Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer." J Clin Oncol 14(6): 1787-97.
	44	King, D. J., P. Antoniow, et al. (1995). "Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy." Br J Cancer 72(6): 1364-72.
	45	Scott, A. M., E. Rosa, et al. (1995). "In vivo imaging and specific targeting of P-glycoprotein expression in multidrug resistant nude mice xenografts with [125I]MRK-16 monoclonal antibody." Nucl Med Biol 22(4): 497-504.
↓	46	Welt et al., 1994, Phase I/II Study of Iodine 131-Labeled Monoclonal Antibody A33 in Patients With Advanced Colon Cancer. J. Clin. Oncol. 12:1561-71

NY02:524633.3

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.